IQVIA has taken a leading role in addressing data access challenges by partnering in the development and validation of the Simulacrum. This is a synthetic oncology dataset structured to model properties of the data collected within England’s national registry, the Cancer Analysis System (CAS), one of the largest and most detailed population-based cancer databases in the world.
Simulacrum is generated using sophisticated algorithms and privacy protecting processes to ensure that it contains no actual patient data. IQVIA has leveraged Simulacrum to accelerate real-world insight generation from the actual underlying CAS data. Through this innovative approach, IQVIA has already performed more than 50 clinically relevant and statistically precise studies that answer critical questions about cancer patients and their treatments without compromising patient confidentiality.
In 2022-3, IQVIA piloted an updated version of Simulacrum based on CAS Molecular Diagnostics data, a new dataset that provides information on somatic biomarker testing in routine clinical practice. The outputs of that pilot were published in PHUSE and in a poster presented at ISPOR: